Programmed death protein-1/ligand-1 (PD-1/PD-L1) inhibitors have shown promising clinical prospects as potential treatment for hepatocellular carcinoma in phase 1–3 studies12,15–17. Here, PDCD1 is linked to hepatocellular carcinoma.